CN118369334A - 新型蛋白 - Google Patents

新型蛋白 Download PDF

Info

Publication number
CN118369334A
CN118369334A CN202280081085.3A CN202280081085A CN118369334A CN 118369334 A CN118369334 A CN 118369334A CN 202280081085 A CN202280081085 A CN 202280081085A CN 118369334 A CN118369334 A CN 118369334A
Authority
CN
China
Prior art keywords
protein
fusion protein
polypeptide
disease
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280081085.3A
Other languages
English (en)
Chinese (zh)
Inventor
瑞贝卡·阿什菲尔德
菲利普·赫胥黎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ducentis Biotherapeutics Ltd
Original Assignee
Ducentis Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ducentis Biotherapeutics Ltd filed Critical Ducentis Biotherapeutics Ltd
Publication of CN118369334A publication Critical patent/CN118369334A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280081085.3A 2021-11-03 2022-11-03 新型蛋白 Pending CN118369334A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2115803.5 2021-11-03
GBGB2115803.5A GB202115803D0 (en) 2021-11-03 2021-11-03 Novel proteins
PCT/GB2022/052764 WO2023079278A1 (en) 2021-11-03 2022-11-03 Novel proteins

Publications (1)

Publication Number Publication Date
CN118369334A true CN118369334A (zh) 2024-07-19

Family

ID=78828504

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280081085.3A Pending CN118369334A (zh) 2021-11-03 2022-11-03 新型蛋白

Country Status (10)

Country Link
US (1) US20250026805A1 (cg-RX-API-DMAC7.html)
EP (1) EP4426719A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542096A (cg-RX-API-DMAC7.html)
KR (1) KR20240099427A (cg-RX-API-DMAC7.html)
CN (1) CN118369334A (cg-RX-API-DMAC7.html)
AU (1) AU2022381844A1 (cg-RX-API-DMAC7.html)
CA (1) CA3236737A1 (cg-RX-API-DMAC7.html)
GB (1) GB202115803D0 (cg-RX-API-DMAC7.html)
IL (1) IL312470A (cg-RX-API-DMAC7.html)
WO (1) WO2023079278A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
EP1171154A2 (en) 1999-04-13 2002-01-16 Schering Corporation Uses of mammalian ox2 protein and related reagents
WO2008089022A2 (en) 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Also Published As

Publication number Publication date
KR20240099427A (ko) 2024-06-28
WO2023079278A1 (en) 2023-05-11
IL312470A (en) 2024-06-01
EP4426719A1 (en) 2024-09-11
CA3236737A1 (en) 2023-05-11
GB202115803D0 (en) 2021-12-15
JP2024542096A (ja) 2024-11-13
US20250026805A1 (en) 2025-01-23
AU2022381844A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
KR102498901B1 (ko) Cd200 돌연변이체 및 그의 용도
KR20160130463A (ko) 다량체 Fc 단백질
JP7097293B2 (ja) ヒトFc受容体に結合する融合タンパク質
US20210214434A1 (en) Variants with fc fragment having an increased affinity for fcrn and an increased affinity for at least one receptor of the fc fragment
US20250026805A1 (en) Novel proteins
JP2025515191A (ja) 新規cd200融合タンパク質
CN121605120A (zh) Cd200融合蛋白
US20260116951A1 (en) Novel cd200 fusion proteins
TW202519543A (zh) TNF-α變體融合分子
EA042608B1 (ru) Мутант cd200 и его применения
CN121930341A (zh) Tl1a结合分子及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination